ENHERTU® Demonstrates Efficacy in HER2 Positive Metastatic Breast Cancer Patients
Clinical Activity of ENHERTU®
In recent studies, ENHERTU® has demonstrated significant clinical activity in patients suffering from HER2 positive metastatic breast cancer. Particularly, those with brain metastases have shown a remarkable response.
Key Findings
- 12% of patients experienced interstitial lung disease (ILD).
- Median time to first onset of ILD was 5.5 months.
- Those treated with ENHERTU at 5.4 mg/kg displayed improved outcomes.
These findings position ENHERTU® as a critical option in the oncology arsenal against HER2 positive metastatic breast cancer.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.